Valuation GSK plc

Equities

Market Closed - London S.E. Other stock markets 11:35:04 2026-01-16 EST			5-day change	1st Jan Change
1,816.50 ^GBX	-1.70%		-3.69%	-0.44%

01-16	Where the Money's Moving
01-16	Some drugmakers quietly concerned about legal risk with speedy FDA review program	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Capitalization ¹	66,801	80,458	58,381	59,112	54,944	72,880	72,880	-
Change	-	20.44%	-27.44%	1.25%	-7.05%	32.64%	0%	-
Enterprise Value (EV) ¹	87,581	100,296	75,578	74,152	68,039	87,012	84,590	81,517
Change	-	14.52%	-24.65%	-1.89%	-8.24%	27.89%	-2.78%	-3.63%
P/E ratio	11.8x	18.6x	3.93x	11.9x	21.3x	13.4x	11.6x	10.7x
PBR	4.58x	5.34x	5.47x	4.4x	4.02x	5.07x	4.24x	3.45x
PEG	-	-0.8x	0x	-0.2x	-0.4x	0x	0.7x	1.27x
Capitalization / Revenue	1.96x	2.36x	1.99x	1.95x	1.75x	2.24x	2.14x	2.04x
EV / Revenue	2.57x	2.94x	2.58x	2.45x	2.17x	2.68x	2.49x	2.29x
EV / EBITDA	9.19x	8.85x	7.23x	6.37x	6.36x	7.73x	7.14x	6.46x
EV / EBIT	9.83x	11.4x	9.27x	8.44x	7.44x	9.05x	8.24x	7.31x
EV / FCF	16.2x	22.6x	12.1x	13.6x	13x	19.1x	13.9x	12.3x
FCF Yield	6.17%	4.42%	8.28%	7.36%	7.67%	5.23%	7.22%	8.15%
Dividend per Share ²	1	1	0.6125	0.58	0.61	0.6476	0.6966	0.7402
Rate of return	5.96%	4.98%	4.26%	4%	4.53%	3.57%	3.84%	4.07%
EPS ²	1.426	1.082	3.662	1.216	0.632	1.352	1.572	1.704
Distribution rate	70.1%	92.4%	16.7%	47.7%	96.5%	47.9%	44.3%	43.4%
Net sales ¹	34,099	34,114	29,324	30,328	31,376	32,498	34,040	35,653
EBITDA ¹	9,530	11,330	10,449	11,635	10,693	11,252	11,845	12,628
EBIT ¹	8,906	8,806	8,151	8,786	9,148	9,615	10,272	11,149
Net income ¹	5,749	4,385	14,956	4,928	2,575	5,311	6,321	6,904
Net Debt ¹	20,780	19,838	17,197	15,040	13,095	14,132	11,710	8,637
Reference price ²	16.78	20.08	14.38	14.50	13.46	18.16	18.16	18.16
Nbr of stocks (in thousands)	3,982,185	4,006,383	4,060,999	4,076,145	4,080,519	4,012,126	4,012,126	-
Announcement Date	2/3/21	2/9/22	2/1/23	1/31/24	2/5/25	-	-	-

¹GBP in Million²GBP

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
GSK PLC	13.44x	2.68x	7.73x	3.57%	97.55B
ELI LILLY AND COMPANY	45.31x	15.02x	33.36x	0.57%	930B
JOHNSON & JOHNSON	21.34x	5.89x	16.37x	2.36%	527B
ABBVIE INC.	63.59x	7.14x	17.12x	3.05%	379B
ROCHE HOLDING AG	20.49x	5.08x	12.65x	2.84%	371B
ASTRAZENECA PLC	28.83x	5.35x	15.87x	1.73%	292B
NOVARTIS AG	20x	5.35x	12.53x	2.85%	276B
MERCK & CO., INC.	13.93x	4.57x	9.84x	2.97%	270B
NOVO NORDISK A/S	16.84x	5.95x	12.3x	2.99%	268B
AMGEN INC.	25.84x	6.13x	10.48x	2.89%	178B
Average	26.96x	6.32x	14.82x	2.58%	358.85B
Weighted average by Cap.	31.54x	8.05x	18.81x	2.16%